Nikolaus Buchmann1, Till Ittermann, Ilja Demuth, Marcello R P Markus, Henry Völzke, Marcus Dörr, Nele Friedrich, Markus M Lerch, Raul D Santos, Sabine Schipf, Elisabeth Steinhagen-Thiessen. 1. Department of Cardiology, Benjamin Franklin Campus, Charité - University Medical Center Berlin; Institute for Community Medicine, University Medical Center Greifswald; Biology of Aging Group, Department of Endocrinology and Metabolic Medicine (including Lipid Metabolism), Charité - University Medical Center Berlin, corporate member of Free University Berlin and Humboldt University of Berlin; Berlin Institute for Health Research at Charité - University Medical Center Berlin, BCRT - Berlin Center for Regenerative Therapy; Department of Internal Medicine B, University Medical Center Greifswald; German Center for Diabetes Research (DZD), Greifswald Site, Greifswald; German Center for Cardiovascular Research (DZHK), Greifswald Site, Greifswald; Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Greifswald; Department of Internal Medicine A, University Medical Center Greifswald; Lipid Clinic, Heart Institute (InCor), Medical Teaching Hospital, University of São Paulo, Brazil.
Abstract
BACKGROUND: An inverse association between lipoprotein(a) (Lp[a]) and type 2 diabetes mellitus is well documented. However, data on the association of the metabolic syndrome (MetS) with Lp(a) are sparse. METHODS: Cross-sectional data for MetS and Lp(a) were available for 5743 BASE-II and SHIP-0 participants (48.7% men; age 58 [20-85] years) (BASE, Berlin Aging Study; SHIP, Study of Health in Pomerania). The association of MetS and its components with Lp(a) was analyzed by means of median regression adjusted for age, sex, and study. Associations were evaluated for the total population as well as stratified by sex and menopausal status. RESULTS: Overall, 27.6% (n = 1573) of the participants in the two studies had MetS and 22.5% (n = 1291) were premenopausal women. There was an inverse association between MetS and Lp(a) in the whole study sample (β = -11.9, 95% confidence interval [-21.3; -2.6]) as well as in men (β = -16.5 [-28.6; -4.3]). Participants with MetS (whole study sample) had 11.9 mmol/L lower Lp(a). Analogous results were found in postmenopausal women (β = -25.4 [-46.0; -4.8]). In premenopausal women with MetS, Lp(a) levels were higher by 39.1 mg/L on average [12.3; 65.9]) than in premenopausal women without MetS. CONCLUSION: Hormonal aspects and menopausal alterations seem to affect the association between MetS and Lp(a), as the expected inverse association was not present in premenopausal women.
BACKGROUND: An inverse association between lipoprotein(a) (Lp[a]) and type 2 diabetes mellitus is well documented. However, data on the association of the metabolic syndrome (MetS) with Lp(a) are sparse. METHODS: Cross-sectional data for MetS and Lp(a) were available for 5743 BASE-II and SHIP-0 participants (48.7% men; age 58 [20-85] years) (BASE, Berlin Aging Study; SHIP, Study of Health in Pomerania). The association of MetS and its components with Lp(a) was analyzed by means of median regression adjusted for age, sex, and study. Associations were evaluated for the total population as well as stratified by sex and menopausal status. RESULTS: Overall, 27.6% (n = 1573) of the participants in the two studies had MetS and 22.5% (n = 1291) were premenopausal women. There was an inverse association between MetS and Lp(a) in the whole study sample (β = -11.9, 95% confidence interval [-21.3; -2.6]) as well as in men (β = -16.5 [-28.6; -4.3]). Participants with MetS (whole study sample) had 11.9 mmol/L lower Lp(a). Analogous results were found in postmenopausal women (β = -25.4 [-46.0; -4.8]). In premenopausal women with MetS, Lp(a) levels were higher by 39.1 mg/L on average [12.3; 65.9]) than in premenopausal women without MetS. CONCLUSION: Hormonal aspects and menopausal alterations seem to affect the association between MetS and Lp(a), as the expected inverse association was not present in premenopausal women.
Authors: B Bauduceau; F Baigts; L Bordier; P Burnat; F Ceppa; V Dumenil; O Dupuy; J P Le Berre; H Mayaudon; S Paillasson Journal: Diabetes Metab Date: 2005-09 Impact factor: 6.041
Authors: Juan Francisco Sánchez Muñoz-Torrero; Dolores Rivas; Rodrigo Alonso; Leandro Crespo; Alberto Costo; Montaña Roman; Carlos Martín; José Zamorano Journal: South Med J Date: 2012-07 Impact factor: 0.954
Authors: Peggy M Kostakou; George Hatzigeorgiou; Vana Kolovou; Sophie Mavrogeni; Genovefa D Kolovou Journal: Curr Med Chem Date: 2017 Impact factor: 4.530